Podcasts about High Risk

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discuss the continued Legionnaire's outbreak in Harlem, invasive Asia longhorned tick and associated disease, potential Ebola outbreak in the Congo, Florida ending childhood vaccine mandates, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, SARS-CoV-2 spillover into household/domestic dogs, real data demonstrating the benefits of COVID-19 vaccines, states that increase access to COVID-19 vaccines, effective and availability to PAXLOVID, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, the beginning of numerous long COVID clinical studies and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Legionnaires' Disease: In Harlem (NYC Health) 2 dead, dozens sickened by Legionnaires' disease in Westchester County: Officials (NBC News) Invasive longhorned tick found for 1st time in New England (AP News) First person bitten by east Asian longhorned tick (AP News) Invasive, disease-carrying tick found in Maine, the farthest northeast it has been spotted (AP News) Suspected cases rise in DR Congo Ebola outbreak (CIDRAP) Ebola in the Democratic Republic of the Congo (CDC: Travelers' Health)  Patricia Mazzei (NY Times) Florida Moves to End Vaccine Mandates for Schoolchildren (NY Times) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) Influenza-Associated Hospitalizations During a High Severity Season — Influenza Hospitalization Surveillance Network, United States, 2024–25 Influenza Season (CDC: MMWR) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Risk factors for severe outcomes of respiratory syncytial virus infection in children (LANCET: Regional Health Europe) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years (CDC: National Center for Immunization and Respiratory Diseases) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Spillover of SARS-CoV-2 to domestic dogs in COVID-19–positive households: A one health surveillance study (Virus Research) Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula  (Pfizer) Minnesota, New York issue executive orders promoting access to COVID vaccines (CIDRAP) No. 52: Declaring a Disaster in the State of New York Due to Federal Actions Related to Vaccine Access(NY State: Executive Order #52) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Patient-Reported Outcomes of Nirmatrelvir Treatment for High-Risk, Nonhospitalized Adults With Symptomatic COVID-19 (OFID) Real-world effectiveness of nirmatrelvir-ritonavir against severe outcomes of COVID-19 in Taiwan (OFID) PAXLOVID-nirmatrelvir and ritonavir : highlights of prescribing information (Pfizer) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer) PAXCESSTM offers access and affordability options to patients prescribed PAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets) (PAXCESS) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Clinical trials explore how Low-Dose Naltrexone could help people with Long COVID (The Sick Times) Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation (The Sick Times) Research updates, July 29: Stellate ganglion blocks, may help reduce the severity of some symptoms of Long COVID and ME  (The Sick Times) New Long COVID and complex disease center at Mount Sinai set to be a leader in research, clinical care (The Sick Times) RECOVER-TLC announces new Long COVID clinical trials, receives mixed reactions from patient community (The Sick Times) Reaching out to US house representative Letters read on TWiV 1252 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode of the Warner Brothas Podcast, the hosts delve into their predictions for the NFL season, categorizing teams into various tiers based on their performance and potential. They discuss teams in the bottom tier, those with uncertain direction, fun teams with potential, high-risk teams, and contenders. The conversation highlights the complexities of team dynamics, coaching changes, and player performances, providing insights into what fans can expect as the season unfolds. In this episode, the hosts delve into the current state of NFL teams, categorizing them into tiers based on their potential for the upcoming season. They discuss the differences between power rankings and tier rankings, emphasizing the importance of context in evaluating team performance. The conversation shifts to predictions for upcoming games, particularly focusing on the Thursday Night Football matchup. The hosts also share their thoughts on the NBA, critiquing recent comments from the league's commissioner and reflecting on the current state of basketball viewership.   00:00 Introduction to NFL Predictions 01:34 Bottom Tier Teams: New Era 03:58 Teams with Uncertain Direction 10:49 Fun Teams with Direction 14:28 High Risk, High Reward Teams 21:10 Potential Contenders 25:15 Wrap-Up and Final Thoughts 25:53 Team Evaluations: Bears, Rams, Steelers, and Vikings 28:32 High Risk, High Reward: Chargers, Bengals, and Cowboys 32:03 Contenders and the New Era: Broncos and Commanders 38:25 True Contenders: Bills, Chiefs, and 49ers 45:31 Forecasting Future Performance: Teams on the Rise and Fall 50:39 Quarterback Dynamics and Team Strategies 53:03 Thursday Night Football Predictions 56:54 Prime Time Game Analysis 01:00:36 NBA Changes and Fan Reactions   FOLLOW THE BROTHAS ON Instagram -https://www.instagram.com/warnerbrothaspodcast/ TikTok - https://www.tiktok.com/@thewarnerbrothaspodcast Facebook - https://www.facebook.com/warnerbrothaspodcast X - https://x.com/warnerbrospod YouTube - https://www.youtube.com/@thewarnerbrothaspodcast

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.---This podcast is supported by:Ferring Pharmaceuticals https://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.---TIMESTAMPS0:00 - Introduction1:48 - Active Surveillance in Low-Risk Prostate Cancer7:08 - Molecular Testing and Risk Stratification8:28 - Radiation Therapy Approaches20:16 - PSA Recurrence and PSMA PET Scans32:40 - The Role of ADT37:15 - PSMA PET Scans40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer46:54 - Treatment Intensification vs. De-Intensification Trials55:59 - Castration-Resistant Prostate Cancer

This is a "Shortcut" episode. It's a shortened version of this week's more detailed full episode, which is also available on our feed.Craig Semple is a former New South Wales police officer with 25 years' experience in high-risk law enforcement.He shares his journey through stress, burnout and, ultimately, recovery, as detailed in his books The Cop Who Fell to Earth and Getting Back Up Again.You can click here to purchase your copy of The Cop Who Fell to Earth, and Getting Back Up Again.You can learn more about Craig's business, Mentality Plus here.Click here to subscribe to ATC Plus on Apple Podcasts and access all ATC episodes early and ad-free, as well as exclusive bonus episodes. Join our Facebook Group here.Do you have information regarding any of the cases discussed on this podcast? Please report it on the Crime Stoppers website or by calling 1800 333 000.For Support: Lifeline on 13 11 1413 YARN on 13 92 76 (24/7 crisis support phone line for Aboriginal and Torres Strait Islander peoples)1800RESPECT: 1800 737 732Blue Knot Helpline: 1300 657 380CREDITS:Host: Meshel LaurieGuest: Craig SempleExecutive Producer/Editor: Matthew TankardGET IN TOUCH:https://www.australiantruecrimethepodcast.com/Follow the show on Instagram @australiantruecrimepodcast and Facebook Send us a question to have played on the show by recording a voice message here.Email the show at AusTrueCrimePodcast@gmail.com Hosted on Acast. See acast.com/privacy for more information.

Some cryptos stand out for their dynamic movements and substantial possibilities. As markets evolve, certain tokens attract attention for their rapid fluctuations and appealing potential. Looking forward, specific projects may lead to significant gains, though accompanied by considerable volatility. This analysis explores which tokens might deliver the largest returns next year. Hyperliquid: The Gas-Free Speedster Aiming to Rewrite DeFi Hyperliquid runs on a fresh base chain built for fast moves. Its own voting system, called HyperBFT, locks trades in seconds while keeping them safe. Every order sits on the chain, so anyone can check the book at any time. Traders zip in and out of endless future swaps without paying gas. This makes the service feel like a top web app, yet it stays fully open and public. A team of sharp minds from Harvard, Caltech, and MIT guides the code, and they fund it themselves, keeping choices clear of outside pull. Many users now hunt for lower fees and faster trades; that trend lifts chains like Solana and Arbitrum. Hyperliquid goes further by cutting fees to zero and keeping the book on-chain, a combo few rivals match. If the bull run keeps warming, fresh volume could rush to places that feel smooth yet fair. Early signs show tight spreads and lively flow, hinting that the idea clicks with pro and casual players alike. While no one can promise price moves, a lean set-up, clear vision, and growing need for speed make the coin one to watch this cycle. XYZVerse Sets a New Trend, Could This be the Next 50X Meme Coin? The buzz around XYZVerse is real. As the first-ever all-sports meme token, it is going to break records in the meme coin space, targeting 50X growth upon launch. The current presale gives early investors the chance to grab $XYZ tokens at a significantly discounted price, far below the expected listing price. Bullish Mood on $XYZ XYZVerse is already featured on CoinMarketCap where the community has shown a strongly bullish mood on this coin, with 95% voters anticipating $XYZ to grow. XYZ was further noticed by reputable crypto influencers. DanjoCapitalMaster, who has close to 800,000 followers, recently expressed his support for the project, calling XYZVerse a "moonshot opportunity." More Than Just a Meme Coin Unlike most meme coins that ride trends without much substance, XYZVerse is setting a new trend. It is blending the high-energy world of sports with the viral nature of meme culture. And it's working. The presale is moving fast, with early buyers locking in tokens at a fraction of what some believe could be its future value. Right now, XYZVerse is still in its presale phase, but demand is high. The price has already climbed from $0.0001 in Stage 1 to $0.005 by Stage 13, with over $15 million already raised. Investors who got in early have secured a steep discount, and with a target listing price of $0.1, those numbers have people paying attention. Still Time to Get in Before the Presale Ends Beyond just hype, XYZVerse has a structured tokenomics model aimed at long-term sustainability. A share of 15% is allocated to liquidity to create a solid market foundation.To reward its community via airdrops and bonuses, the team has put aside 10% of the total supply. Moreover, a big chunk of 17.13% is designated for deflationary burns, which could reduce supply and drive demand for $XYZ over time. A Community-Driven Project With Big Plans One thing setting XYZVerse apart is how it engages its community. The team recently launched the Ambassador Program, giving users the chance to earn free tokens by supporting the project. And that's just the start - there are already talks with major sports celebrities to help boost visibility. The recent partnership with decentralized sportsbook bookmaker.XYZ underscores XYZVerse's commitment to expanding its utility. It's a big move that gives the community something to actually use. As part of the deal, $XYZ holders get a special bonus on their first bet -...

Cartel Drug Boats Targeted by Fighter Jets in High-Risk Chase The Police Off The Cuff team is covering the latest news regarding the deployment of fighter jets in the united states and South America. Bill and Mike provide detailed analysis of the situation, including the ongoing efforts of law enforcement to combat the cartel presence. Stay informed with the latest US news.

Craig Semple is a former New South Wales police officer with 25 years' experience in high-risk law enforcement. He shares his journey through stress, burnout and, ultimately, recovery, as detailed in his books The Cop Who Fell to Earth and Getting Back Up Again.You can click here to purchase your copy of The Cop Who Fell to Earth, and Getting Back Up Again.You can learn more about Craig's business, Mentality Plus here.Click here to subscribe to ATC Plus on Apple Podcasts and access all ATC episodes early and ad-free, as well as exclusive bonus episodes. Join our Facebook Group here.Do you have information regarding any of the cases discussed on this podcast? Please report it on the Crime Stoppers website or by calling 1800 333 000.For Support: Lifeline on 13 11 1413 YARN on 13 92 76 (24/7 crisis support phone line for Aboriginal and Torres Strait Islander peoples)1800RESPECT: 1800 737 732Blue Knot Helpline: 1300 657 380CREDITS:Host: Meshel LaurieGuest: Craig SempleExecutive Producer/Editor: Matthew TankardGET IN TOUCH:https://www.australiantruecrimethepodcast.com/Follow the show on Instagram @australiantruecrimepodcast and Facebook Send us a question to have played on the show by recording a voice message here.Email the show at AusTrueCrimePodcast@gmail.com Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Protector Culture Podcast, Jimmy Graham is joined by longtime friend and Able Shepherd teammate, Pony Anderson. The two swap stories from the early days of the Able Shepherd program and dive into the roots of reality-based simulation training. From lessons learned in the field to the evolution of tactics that shaped the curriculum, this conversation offers a rare behind-the-scenes look at the mindset and mission that built a movement. Don't miss this trip down memory lane with two protectors who helped set the standard. Who's Jimmy Graham? Jimmy spent over 15 years in the US Navy SEAL Teams earning the rank of Chief Petty Officer (E7). During that time, he earned certifications as a Sniper, Joint Tactical Air Controller, Range Safety Officer for Live Fire, Dynamic Movement and Master Training Specialist. He also served for 7 years as an Operator and Lead Instructor for an Elite Federal Government Protective Detail for High-Risk and Critical environments, to include; Kirkuk, Iraq, Kabul, Afghanistan, Beirut, Lebanon and Benghazi, Libya. During this time he earned his certification for Federal Firearms Instructor, Simunition Scenario Qualified Instructor and Certified Skills Facilitator. Jimmy has trained law enforcement on the Federal, State, and Local levels as well as Fire Department, EMS and Dispatch personnel. His passion is to train communities across the nation in order to enhance their level of readiness in response to active shooter situations. Make sure you subscribe and stay tuned to everything we are doing. Want to get more training? - https://ableshepherd.com/ Need support? https://able-nation.org/ Follow us on: Facebook - https://www.facebook.com/ableshepherd Instagram - ​​https://www.instagram.com/ableshepherd/ Youtube - https://www.youtube.com/@ableshepherd

00:00 INTRO00:33 What's your #1 concern going into the Banjo Bowl?03:38 What are you most optimistic for in the Banjo Bowl?06:32 Which Bomber will be the difference maker in the Banjo Bowl?09:57 Bomber Blue Print17:36 Grey Cup pretender or contender?19:32 Which matchup holds the most weight?22:04 Who is your favourite CFL, and CFL Canadian Runningback?26:10 High Risk predictions!#winnipegbluebombers  #forthew #cfl #winnipegjets #canadianfootball #winnipeg #podcast #sports #manitoba #bluebombers  #roughriders #Elks #football #bclions Fahrenheit Airbrushing - https://www.facebook.com/fahrenheitairbrushing?mibextid=LQQJ4dFOLLOW US ON...Website: https://www.raybennysports.comFacebook: https://www.facebook.com/raybennysportsBluesky: https://bsky.app/profile/raybennysports.bsky.socialInstagram: https://www.instagram.com/raybennysports/Twitter: https://twitter.com/raybennysportsTikTok - https://www.tiktok.com/@raybennysportsApple Podcasts: https://apple.co/3rPuut8Spotify: https://spoti.fi/3rO0AFFLinktree: https://linktr.ee/raybennysportsReddit: https://www.reddit.com/r/raybennytalksports/Discord: https://discord.gg/VcHXqu7mSupport: https://www.buzzsprout.com/1864423/supportSupport the show

Nate digs in on 8 players who might have lots of potential but also have tons of risk:Mikko Rantanen: 0:53Elias Pettersson: 2:27Roman Josi: 3:38Zach Hyman: 5:09Mackenzie Weegar: 9:59Pavel Dorofeyev: 11:24Dougie Hamilton: 12:43Gabriel Landeskog: 13:53Download the Apples & Ginos 2025-26 Fantasy Hockey Draft Guide here:https://www.patreon.com/posts/apples-ginos-26-137903611?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_linkJoin the Apples & Ginos Patron League to compete against the best fantasy hockey managers on the planet! Find your tier of competition and test your mettle week in and week out:https://applesandginos.com/apl/

Alex Misery is unhinged. A man of many hats, most of whom are insane. He's a vocalist for the band Twisted Misery. He shreds on the skateboard. But where most of our listeners will know Misery is from his time in the ring. High Risk is a statement that has little to no meaning for Misery. Misery joined the National Wrestling Alliance at the first Samhain back in 2023. Before his time with the NWA, Misery was a mainstay in the Florida Independent Scene, gaining a bit of notoriety working for Coastal Championship restling and FTW Wrestling.A not-so-well-kept secret is that Misery is also a second-generation wrestler; he's the son of "El Leon" Apolo. Apolo is a former NWA World Tag Team Champion (as part of the TNA era of the NWA) and the North American Champion. His father was a well-established superstar in Puerto Rico before becoming a mainstay in the United States. Similarly, Alex spent time working in Puerto Rico; however, his time was spent at World Wrestling Council, the rival to IWA Puerto Rico. We will talk to Alex Misery tonight. We will speak to him about his time in Puerto Rico, getting established in Florida in the independents, wrestling from under his father's shadow, and becoming a fixture of the NWA. Please join us for this very unique interview.

A round of high-stakes hypotheticals gets real: the $100K-per-grape gamble, trading 10 years for $20M, a 10-second daily rewind, who represents humanity to aliens, and our “never show the monster” horror blueprint. Where do you draw the line? Thank you for being part of this crowd!Want the worst advice imaginable from the 5 of us? Leave us a voicemail with your issue, and we may share it on one of the next podcasts! We don't want people calling in asking for advice on how to get through their divorce, but more like, "How can I get my husband to stop clipping his toenails in the living room?". If you've got some burning questions, leave us a message! 801-997-021300:00 - Start!00:01:40 - The $100K-per-grape dilemma: how many would you risk?00:08:32 - Life insurance logic & cotton-candy grapes00:13:06 - Aliens land: who speaks for humanity?00:18:22 - Worst gifts we've ever received (it gets weird)00:20:52 - Space Jam bedroom & childhood nostalgia00:22:43 - Would you trade 10 years for $20M?00:24:17 - Who dies first in our horror movie?00:26:43 - “Never show the monster”: our horror-film blueprint00:31:14 - The 10-second rewind power: uses & abuses00:33:23 - Nic Cage, “Next,” and action-actor hot takes00:36:01 - Top five times you almost died (afterlife stat screen)00:37:00 - Brain-eating amoeba & ocean fears00:39:24 - The 50/50 age button: younger or older?00:40:59 - Wrap-up & Crowd thank-youReddit- Our Subreddit: https://www.reddit.com/r/FivesACrowd- Our Account: https://www.reddit.com/user/FivesACrowdPodcastFollow Our Personal AccountsAustin - https://allmylinks.com/austinspomerCam - https://www.instagram.com/effinburch/Chris - https://www.instagram.com/thechrishummel/Tony - https://www.instagram.com/theonlytonyc/Zach - https://www.instagram.com/zvanbeekum/Hashtags#JoinTheCrowd #HitTheBell #PodcastP.O. Box**Please no packages, letters only**Five's A Crowd Podcast1123 N Fairfield Rd #1373 Layton, UT 84041

On this week's Prospect Podcast, Geoff Pontes, JJ Cooper and Mark Chiarelli take a look at some Top 100 hitting prospects who are extremely low risk, and some who have a flaw that could trip them up. And Mark takes a look at what's going on with Pirates RHP Bubba Chandler. Plus Prospect Soapboxes.(00:00) When we talk about risk with hitting prospects, what are we looking at? How Has It Changed?(04:00) Why Tigers SS Kevin McGonigle checks so many boxes as a prospect(16:25) Cardinals SS JJ Wetherholt has very few risk factors(18:00) Royals C Carter Jensen does a lot of things very well as a hitter(21:35) Tigers CF Max Clark has bat control, makes good swing decisions and hits the ball hard.(30:00) What makes a hitter a very risky prospect to develop?(37:00) Spencer Jones and Tony Blanco are examples of massive power with contact concerns(41:15) Jordan Lawlar is risky in a different way(44:00) New Minnesota Twin Eduardo Tait has one concerning flaw (47:20) What's going on with Pirates RHP Bubba Chandler? How has his prospect status changed?(55:00) Geoff's Prospect Soapbox: Cardinals OF Joshua Baez(59:50) JJ's Prospect Soapbox: Marlins OF Luis Cova(1:01:55) Mark's Prospect Soapbox: A's SS Edgar MonteroRula patients typically pay $15 per session when using insurance. Connect with quality therapists and mental health experts who specialize in you at https://www.rula.com/foul! #rulapodOur Sponsors:* Check out Indeed: https://indeed.com/BASEBALLAMERICA* Check out TruDiagnostic and use my code BA2022 for a great deal: https://www.trudiagnostic.comSupport this podcast at — https://redcircle.com/baseball-america/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In July, the Trump administration released what it calls an AI action plan. In it, along with several executive orders, the White House lays out its vision for building and expanding the country's AI infrastructure.  Key tenets of that vision include removing regulatory hurdles and accelerating US dominance in the industry. It also has broad energy and security implications. So how could the administration's high-risk, high-reward approach increase US market share in AI? Will it create tensions with major AI companies while potentially democratizing access to AI capabilities? And how does the plan diverge from Biden-era AI support, especially around environmental and energy considerations? To discuss the action plan, we convened some of the leading AI experts at the Center for Global Energy Policy in early August, and this week on Columbia Energy Exchange we are sharing an audio recording of their discussion.  David Sandalow, CGEP's inaugural fellow and the host of the AI, Energy and Climate podcast, moderated the panel. David also co-directs the Energy and Environment Concentration at the School of International and Public Affairs at Columbia University and was the lead author of the “Artificial Intelligence for Climate Change Mitigation Roadmap” report for the Innovation for Cool Earth Forum. Aaron Bartnick, Jared Dunnmon, and Ashley Finan joined David on the webinar. Aaron Bartnick is a global fellow at CGEP, where he focuses on technology and economic security. He also serves as chief of staff at the neural engineering company Science Corporation and as a fellow at Carnegie Mellon University's Critical Technology Initiative. Jared Dunnmon is a non-resident CGEP fellow and the co-founder and chief scientist of a maritime logistics startup. He previously served in the Department of Defense as technical director for artificial intelligence at the Defense Innovation Unit, was vice president of future technologies at battery firm Our Next Energy, and was an early team member at Snorkel AI. Ashley Finan is a CGEP global fellow who previously served in senior leadership roles at Idaho National Laboratory, where she worked on nuclear energy and national security issues.  Credits: Hosted by Jason Bordoff and Bill Loveless. Produced by Mary Catherine O'Connor, Caroline Pitman, and Kyu Lee. Engineering by Gregory Vilfranc.  

Hi Listeners. I'd love to hear from you. Send an email to Janet@jesteinkamp. It is not possible to respond to your Fan Mail posts directly.Join me as I walk you through the challenges and some solutions when you need to respond to invitations scheduled on or related to high-risk days. So often, these events include your adult child. So what then?!How do our adult children decide whether to attend family events, annual festivities where you'll be present, etc?In this episode, I provide a decision-making process to help you choose whether to attend high-risk social events.What happens when a social invitation coincides with a high-risk day during estrangement? What should a parent do? Think through this challenging decision: why we might feel pressure to attend, how adult children are also navigating similar questions, and when choosing to attend—or decline—might be the healthiest path. Past episodes referenced in this conversation:Cracking the Busy Body Code: Managing Your MessageFriendly Advocate or Flying Monkey? (Short)Support the showFor more information, please go to https://www.WhenOurAdultChildrenWalkAway.com to find resources, strategies and tips to prepare to repair! The continuum of estrangement discussed today can be found at https://www.togetherestranged.org/levels-of-estrangement. The stories, examples, reflections, and perspectives shared in this podcast are based on my professional work as an estrangement coach and my personal estrangement journey. Any examples, characters, or stories referenced are either drawn from my own lived experience or represent a composite of multiple real-life situations shared with me over time. The intention of this podcast is not to accuse, label, or defame any individual but to provide insight, validation, and support for those navigating the complexities of family estrangement. All opinions expressed are my own and are shared with you, the listener, from a place of healing and learning.

Reporting a sexual assault is deeply challenging in any context, so what happens when you’re in a war-torn region, where infrastructure has crumbled, and justice systems are non-existent? Associate Professor David Wells retired as Victoria's top forensic physician in 2013. Since then, his work has taken him to some of the world's most volatile places, including Gaza, the West Bank, and other corners of the globe where conflict has gutted hospitals and justice systems alike. There, he's helped build systems to support survivors of sexual violence, often under near impossible conditions. In this episode, David takes us to the front lines of forensic medicine in a conflict zone, and reflects on the challenge of treating survivors where hospitals barely exist, and navigating the cultural, legal and ethical landmines that surround violence in war. What does it take to offer care when the world is falling apart? And what role can forensic medicine play, not just in accountability, but in healing? If you or anyone you know needs support, call Lifeline on 131 114, beyondblue on 1800 512 348, Kids Helpline on 1800 55 1800, or the National Sexual Assault, Domestic and Family Violence Counselling Service on 1800RESPECT (1800 737 732).See omnystudio.com/listener for privacy information.

August 15, 2025 ~ Collegiate athletes, especially women, face increased stalking risks due to their public profiles and social media presence. Michael Matthews, detective sergeant evidence technician in the Special Victims Unit for the University of Michigan Police Department, talks with Chris, Lloyd, and Jamie about how universities offer resources to protect these athletes and students.

Cam Heyward has already been paid a large roster bonus and has some leverage against the Steelers. Heyward stated he'll sit out of games, but Mike doesn't think he'll be willing to do that. Mike thinks Heyward's camp leaked the news to Adam Schefter.

Hour 2 with Joe Starkey: Cam Heyward has already been paid a large roster bonus and has some leverage against the Steelers. Doug Whaley thinks Cam Heyward's reps didn't do a good enough job of working on Cam's contract. Micah Parsons seems miserable at Cowboys practice. Not many changes on the Steelers depth chart.

In the dead of night, Friday October 15, 2021, on the rugged coastline of Western Australia, four-year old Cleo Smith is abducted from a tent at a campsite. Her disappearance sparked a massive police search and captured the nation’s attention with ‘round the clock media coverage. The child was found 18 days later in what was one of Australia’s most successful police operations. Who abducted her….and why?See omnystudio.com/listener for privacy information.

Jimmy Graham sits down with Chris Brewer, author of Old Scroll Ranger, to dive into his time in Ranger Battalion and the unforgettable stories that shaped his journey. Purchase Old Scroll Ranger here: https://a.co/d/3uE5qS1 Who's Jimmy Graham? Jimmy spent over 15 years in the US Navy SEAL Teams earning the rank of Chief Petty Officer (E7). During that time, he earned certifications as a Sniper, Joint Tactical Air Controller, Range Safety Officer for Live Fire, Dynamic Movement and Master Training Specialist. He also served for 7 years as an Operator and Lead Instructor for an Elite Federal Government Protective Detail for High-Risk and Critical environments, to include; Kirkuk, Iraq, Kabul, Afghanistan, Beirut, Lebanon and Benghazi, Libya. During this time he earned his certification for Federal Firearms Instructor, Simunition Scenario Qualified Instructor and Certified Skills Facilitator. Jimmy has trained law enforcement on the Federal, State, and Local levels as well as Fire Department, EMS and Dispatch personnel. His passion is to train communities across the nation in order to enhance their level of readiness in response to active shooter situations.   Make sure you subscribe and stay tuned to everything we are doing. Want to get more training? - https://ableshepherd.com/ Need support? https://able-nation.org/ Follow us on: Facebook - https://www.facebook.com/ableshepherd Instagram - ​​https://www.instagram.com/ableshepherd/ Youtube - https://www.youtube.com/@ableshepherd

This episode of Kiwi Birth Tales is proudly brought to you by Your Birth Project. In this episode of Kiwi Birth Tales, I speak to Emma. Some of the topics we cover:Emma was 43 when she gave birth to Remi Years of infertility IVFEgg Donor Covid impacting journey"High Risk" pregnancy Emergency Csection (had already decided on Csection being mode of delivery) 3 weeks in NICU Donor Milk Struggled with breastfeeding Mental health Your Birth Project Online Hypnobirthing Coursehttps://www.fertilityassociates.co.nz/book-a-free-nurse-consultPlease seek support for any mental health concerns, some helpful links are below:Mental Health in PregnancyPerinatal Depression and Anxiety Aotearoa Plunket - Dads Mental HealthLittle Shadow - Private Counselling NZFind me @kiwibirthtales and @yourbirthproject Hosted on Acast. See acast.com/privacy for more information.

In this episode, Brent Sanders speaks with former NSW Police officer Justyn Backhouse, who spent 25 years on the front lines of law enforcement. From high-speed pursuits to complex aerial rescues, Justin’s career spanned some of the most intense and demanding roles in policing. But behind the action was a hidden cost. Diagnosed with PTSD in 2021, Justin turned to writing to process his experiences. The result is Hidden Scars: From Crime Scenes to Crisis – The Price of Service, a powerful memoir that reveals the unseen toll of a life spent in uniform. This episode makes mention of self-harm. If you or anyone you know needs someone to speak to, call LifeLine on 13 11 14.See omnystudio.com/listener for privacy information.

Welcome back to the show! In this episode, Steve discusses a case study based on real investments made by real investors! So what do investors do when the bank thinks that their investment is "too risky" to back with a loan? Tune in to the show and find out! Please remember that Steve is always available to talk with his listeners! Just send your questions, comments, and concerns to AskSteve@TotalWealthAcademy.com today!

RAIDERS Preseason Depth Chart BREAKDOWN! Micah Parsons Trade Rumors, Tom Brady at Camp 00:00 - Raiders Season Countdown & Period Math 00:38 - Raiders vs Seahawks Preseason Primer 03:35 - Trivia Fumble: AFC East History 04:55 - First Depth Chart Reaction: Offense 06:10 - Jackson Powers-Johnson vs Jordan Meredith 07:45 - Backup QB Battle: AOC vs Cam Miller 10:25 - Pete Carroll's Depth Chart Philosophy 11:45 - No Throwaway Players: Why Every Snap Matters 13:34 - RB2 Battle: Zamir White vs Raheem Mostert 14:18 - Dante Thornton WR1 Potential? 16:53 - Defense Depth Chart: Surprises & Trends 17:45 - Thomas Booker = Hidden Gem? 20:11 - Defensive Line: High Ceiling or High Risk? 22:12 - Linebackers = Raiders' Best Unit? 24:22 - Raiders DREAM Trade: Micah Parsons Breakdown 27:17 - Jerry Jones vs Micah Parsons: Contract Drama 30:34 - What Would You Trade for Micah Parsons? 35:37 - A GOAT Shows Up at Camp (Literally) 36:47 - Tom Brady at Camp: Spy or Motivator? 39:14 - Brandon Hunt: Raiders' Secret Weapon 41:04 - Everyone's Incentivized to Win Now 42:55 - The Booker-for-Bennett Trade Explained 43:22 - Antonio Pierce in Chiefs Red?! 44:54 - Raiders vs Seahawks: What to Expect Tonight 45:17 - Fake News: Raiders Starters Playing? 47:04 - Revenge Game Vibes in the Preseason? 48:23 - Should Starters Play in Preseason? 50:08 - What Do We Want to See Tonight? 52:02 - Young Guys to Watch & Chip Kelly Run Game Hopes 53:29 - Jackson Powers-Johnson = Defensive Tackle?! 54:50 - Kolton Miller Extension: Smart Move 56:19 - What Up Windbags: Wilkins Comments 58:07 - Final Thoughts & Tonight's Live Show Preview  

Stable coins have gotten a lot of news lately...but what are they? Are they here to stay? Is this something community banks are going to have to deal with...whether we like it or not? I don't know, but it is always best to arm ourselves with information because, as my good friend Justin says, "we fear the unknown until we know the fear". I think it's a powerful statement as it pertains to all types of shifts in the industry. Be sure to follow Justin and his business, High Risk Education on LinkedIn. Justin: https://www.linkedin.com/in/justin-muscolino/ High Risk Education: https://www.linkedin.com/company/highriskeducation/about/ And as always, thanks to ICBA Securities for their support and sponsorship! https://www.icba.org/icba-securities

Denver property taxes just doubled on some commercial properties, creating both challenges and opportunities for triple net investment strategies. Commercial real estate expert Kayla Mahoney reveals how multi-tenant diversification approaches are outperforming single-tenant properties while delivering 5-7% cap rates in prime Denver submarkets.

Jimmy Graham sits down with Mark Gerson, author of God Was Right, for a powerful conversation on faith, wisdom, and life lessons. To order the book click here: https://a.co/d/fM11w9I To learn more about Mark: https://www.godwasright.com Who's Jimmy Graham? Jimmy spent over 15 years in the US Navy SEAL Teams earning the rank of Chief Petty Officer (E7). During that time, he earned certifications as a Sniper, Joint Tactical Air Controller, Range Safety Officer for Live Fire, Dynamic Movement and Master Training Specialist. He also served for 7 years as an Operator and Lead Instructor for an Elite Federal Government Protective Detail for High-Risk and Critical environments, to include; Kirkuk, Iraq, Kabul, Afghanistan, Beirut, Lebanon and Benghazi, Libya. During this time he earned his certification for Federal Firearms Instructor, Simunition Scenario Qualified Instructor and Certified Skills Facilitator. Jimmy has trained law enforcement on the Federal, State, and Local levels as well as Fire Department, EMS and Dispatch personnel. His passion is to train communities across the nation in order to enhance their level of readiness in response to active shooter situations. Make sure you subscribe and stay tuned to everything we are doing. Want to get more training? - https://ableshepherd.com/ Need support? https://able-nation.org/ Follow us on: Facebook - https://www.facebook.com/ableshepherd Instagram - ​​https://www.instagram.com/ableshepherd/ Youtube - https://www.youtube.com/@ableshepherd

After their 21 month old daughter Lily was experiencing stomach pains in April of 2024, Nicky and Dan Rankin took her to an Emergency Room and she was then admitted to Children's Hospital at the Anschulz campus in Aurora, Colorado. Shortly after that, Lily was diagnosed with High Risk Neuroblastoma. 16 months later as we enter August of 2025, Lily is doing as well as possible . Dan will discuss what Lily has been through and the Half Triathlon that he has been training for to raise money because of the great treatment that Lily has received at Children's Hospital.

One unstable patient, three departments, and every nurse on alert... Let's break down what really happens during a high-risk STEMI. This episode follows the case of a 62-year old patient from ER to the Cath Lab to the ICU. Nurses Sarah Vance and Caitlyn Nichols help us explore the role of nurses in each stage of care, from stabilizing the patient to placing an Impella device.We cover everything from IV placement and medications to monitoring patients through each phase of care. Learn how to prepare patients for the Cath Lab, manage complications like V-fib and bleeding post-PCI, and support the next team during handoffs. This is a must-listen for nurses involved in cardiac care!Topics discussed in this episode:Case presentation of a 62-year old patientER nurse priorities for STEMI patientsInitial treatment and stabilizationWhy “M.O.N.A.” is an outdated practicePreparing the patient for the Cath Lab teamCath Lab nurse responsibilities and role during PCIHigh-risk PCI vs. standard PCIManaging common complicationsTransitioning from Cath Lab to ICUICU nurse priorities for post-PCI patientsImpella placement and monitoringManaging reperfusion arrhythmiasLong-term care and getting patients off the ImpellaPatient and family educationConnect with Sarah Vance:https://www.instagram.com/iseeu_nurse/Connect with Caitlyn Nichols:https://www.instagram.com/icunursingnotesbycaitlyn/Mentioned in this episode:CONNECT

Five years ago, Jimmy Graham dreamed of walking the El Camino with his two daughters. This year, that dream came true. Join Jimmy and Brian Karch as they reflect on the powerful moments, lessons, and memories from their pilgrimage across Spain.   Who's Jimmy Graham? Jimmy spent over 15 years in the US Navy SEAL Teams earning the rank of Chief Petty Officer (E7). During that time, he earned certifications as a Sniper, Joint Tactical Air Controller, Range Safety Officer for Live Fire, Dynamic Movement and Master Training Specialist. He also served for 7 years as an Operator and Lead Instructor for an Elite Federal Government Protective Detail for High-Risk and Critical environments, to include; Kirkuk, Iraq, Kabul, Afghanistan, Beirut, Lebanon and Benghazi, Libya. During this time he earned his certification for Federal Firearms Instructor, Simunition Scenario Qualified Instructor and Certified Skills Facilitator. Jimmy has trained law enforcement on the Federal, State, and Local levels as well as Fire Department, EMS and Dispatch personnel. His passion is to train communities across the nation in order to enhance their level of readiness in response to active shooter situations.   Make sure you subscribe and stay tuned to everything we are doing. Want to get more training? - https://ableshepherd.com/ Need support? https://able-nation.org/ Follow us on: Facebook - https://www.facebook.com/ableshepherd Instagram - ​​https://www.instagram.com/ableshepherd/ Youtube - https://www.youtube.com/@ableshepherd

In this eye-opening episode, employment attorneys Kristen Prinz and Christina Hynes Mesco explore the complex dynamics of harassment among senior executives—particularly how it impacts women in top leadership roles. Executives often have fewer avenues for reporting sexual harassment than other employees, and women continue to face disproportionate scrutiny and higher standards of behavior in the workplace. At the same time, executives are not immune from being accused of harassment themselves.   Kristen and Christina rely on their own expertise in counseling clients and litigating employment claims to explore the unique position senior women occupy in these conversations and how they can protect themselves and their teams.   Our hosts—experienced employment attorneys—discuss:  ·        Why senior women are often targets   ·        How miscommunications and unclear boundaries can lead to liability  ·        Why retaliation is still one of the most common mistakes companies make  ·        How they advise clients facing these high-stakes issues  ·        What effective organizational responses actually look like  ·        The critical importance of documenting concerns early and clearly  This episode will be instructive for C-suite leaders and aspiring executives, HR professionals and legal counsel, and anyone managing workplace culture and compliance. Whether you're an executive navigating a tricky situation or advising leadership from the wings, this episode offers essential insights on how to lead with integrity, manage risk, and promote healthier workplace culture.       Stay Connected & Learn More:   Kristen Prinz   Christina Hynes Mesco   Christina & Kristen's blog on executive harassment   The Prinz Law Firm

In this episode of the Informed Decisions podcast, I chat with Rob Halligan and Scott Ashmore, co-founders of Shuttle, a platform aiming to democratise access to private equity and venture capital investments.   The conversation dives into the fundamentals of private markets, how they differ from public equity investing, and why early-stage companies often turn to private capital over traditional bank loans. Rob and Scott shed light on the risk-reward profile of venture investing, the importance of diversification, and how Shuttle helps everyday investors participate in an asset class typically reserved for institutions and high-net-worth individuals.   The discussion also explores the mechanics of venture funding - from pre-seed to Series D rounds - highlighting how company valuations are set and the expected timeframes for returns. With Central Bank of Ireland authorisation, Shuttle operates a quarterly investment model, allowing users to gain exposure to a portfolio of vetted startups. The duo outline their vision for the platform, its future expansion into VC fund access, and how it aligns incentives by charging only a modest annual fee and a performance-based profit share.   Key Points: Private vs Public Markets: Private equity involves investing in unlisted companies, offering potentially higher returns but greater risk and illiquidity. Venture Capital Basics: VC is a subset of private equity focused on early-stage, high-growth startups, structured around funding rounds (e.g., Seed, Series A-C). High Risk, High Reward: Venture capital returns follow a power law distribution—few winners generate most of the returns. Diversification is Key: Investors should aim for 50+ holdings to reduce risk; Shuttle structures this via quarterly “drops” of 2–3 companies. Accessibility: Shuttle enables retail investors to participate in venture deals from as little as €250 per quarter. Platform Model: Investors pay €250/year plus a 10% fee only on realised profits, aligning platform and investor interests. Liquidity & Exit: Returns typically take 5–10 years; Shuttle is exploring secondary markets to improve interim liquidity. Market Trends: Private companies are staying private longer; institutional data points to retail access as the next frontier. Educational Focus: Shuttle supports investor understanding through simplified UX, content, and risk-appropriate onboarding. I hope it helps   JoinShuttle.com   Grit by Angela Duckworth – recommended by Rob Halligan. A book about the power of passion and perseverance in achieving success.   Outliers by Malcolm Gladwell – recommended by Scott Ashmore. It explores what makes high achievers different, focusing on the factors that contribute to success.   Disclaimer

In this JCO Article Insights episode, Michael Hughes summarizes “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I am interviewing Dr. Nikhil Munshi on the “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma” by Avet-Loiseau et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. While some patients with multiple myeloma live for decades after treatment, others exhibit refractory or rapidly relapsing disease irrespective of treatment administered. We term this “high-risk myeloma.” Multiple risk stratification systems have been created, starting with the Durie-Salmon system in 1975 and evolving with the advent of novel therapeutics and novel treatment approaches. In 2015, the Revised International Staging System (R-ISS) was introduced, which incorporated novel clinical and cytogenetic markers and remained, until recently, a mainstay of risk stratification in newly diagnosed disease. Myeloma as a field has, just in the past few years, though, undergone explosive changes. In particular, we have seen groundbreaking advances not only in treatments - the introduction of anti-CD38 agents and the advent of cellular and bispecific therapies - but also in diagnostic technology and our understanding of the genetic lesions in myeloma. This has led to the proliferation of numerous trials employing different definitions of high-risk myeloma, a burgeoning problem for patients and providers alike, and has prompted attempts to consolidate definitions and terminology. Regarding cytogenetic lesions, at least, Kaiser et al's federated meta-analysis of 24 therapeutic trials, published here in the JCO in February of 2025 and recently podcasted in an interview with associate editor Dr. Suzanne Lentzsch, posited a new cytogenetic classification system to realize a shared platform upon which we might contextualize those trial results. This article we have here by Dr. Avet-Loiseau, Dr. Munshi, and colleagues, published online in early June of this year and hot off the presses, is the definitive joint statement from the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG). What is high-risk multiple myeloma for the modern era? The IMS and IMWG Genomics Workshop was held in July 2023 and was attended by international myeloma experts, collaborating to reach consensus based on large volumes of data presented and shared. The datasets included cohorts from the Intergroupe Francophone du Myélome (IFM); the HARMONY project, comprised of multiple European academic trials; the FORTE study, findings from which solidified KRd as a viable induction regimen; the Grupo Español de Mieloma Múltiple (GEM) and the PETHEMA Foundation; the German-Speaking Myeloma Multicenter Group (GMMG); the UK-based Myeloma XI, findings from which confirmed the concept of lenalidomide maintenance; Emory 1000, a large, real-world dataset from Emory University in Atlanta; the Multiple Myeloma Research Foundation Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) dataset; and some newly diagnosed myeloma cohorts from the Mayo Clinic. Data were not pooled for analyses and were assessed individually - that is to say, with clear a priori understanding of whence the data had been gathered and for what original purposes. Consensus on topics was developed based on the preponderance of data across studies and cohorts. In terms of results, substantial revisions were made to the genomic staging of high-risk multiple myeloma, and these can be sorted into three major categories: A) alterations to the tumor suppressor gene TP53; B) translocations involving chromosome 14: t(14;16) (c-MAF overexpression), t(14;20) (MAFB overexpression), and t(4;14) (NSD2 overexpression); and C) chromosome 1 abnormalities: deletions of 1p or additional copies of 1q. In terms of category A, TP53 alterations: Deletion of 17p is present in up to 10% of patients at diagnosis and is enriched in relapsed or refractory disease. This is well-documented as a high-risk feature, but the proportion of the myeloma cells with deletion 17p actually impacts prognosis. GEM and HARMONY data analyses confirmed the use of 20% clonal cell fraction as the optimal threshold value for high-risk disease. That is to say, there must be the deletion of 17p in at least 20% of the myeloma cells on a FISH-analysis of a CD138-enriched bone marrow sample to qualify as high-risk disease. TP53 mutations can also occur. Inactivating mutations appear to have deleterious effects similar to chromosomal losses, and the biallelic loss of TP53, however it occurs, portends particularly poor prognosis. This effect is seen across Myeloma XI, CoMMpass, and IFM cohorts. Biallelic loss is rare, it appears to occur in only about 5% of patients, but next-generation sequencing is nevertheless recommended in all myeloma patients. Category B, chromosome 14 translocations: Translocation t(14;16) occurs in about 2% to 3% of patients with newly diagnosed disease. In the available data, primarily real-world IFM data, t(14;16) almost always occurs with chromosome 1 abnormalities. Translocation t(4;14) occurs in about 10% to 12% of newly diagnosed disease, but only patients with specific NSD2 alterations are, in fact, at risk of worse prognosis, which clinically appears to be about one in every three of those patients. And so together, the CoMMpass and Myeloma XI data suggest that translocation t(4;14) only in combination with deletion 1p or gain or amplification of 1q correlates with worse prognosis. Translocation t(14;20) occurs in only 2% of newly diagnosed disease. Similar to translocation t(4;14), it doesn't appear to have an effect on prognosis, except if the translocation co-occurs with chromosome 1 lesions, in which case patients do fare worse. Overall, these three translocations - t(14;16), t(4;14), and t(14;20) - should be considered high-risk only if chromosome 1 aberrations are also present. In terms of those chromosome 1 aberrations, category C, first deletions of 1p: Occurring in about 13% to 15% of newly diagnosed disease, deletion 1p eliminates critical cell checkpoints and normal apoptotic signaling. In the IFM and CoMMpass dataset analyses, biallelic deletion of 1p and monoallelic deletion of 1p co-occurring with additional copies of 1q denote high-risk. In terms of the other aberration in chromosome 1 possible in myeloma, gain or amplification of 1q: This occurs in up to 35% to 37% of newly diagnosed disease. It upregulates CKS1B, which is a cyclin-dependent kinase, and ANP32E, a histone acetyltransferase inhibitor. GEM and IFM data suggest that gain or amplification of 1q - there was no clear survival detriment to amplification - is best considered as a high-risk feature only in combination with the other risk factors as above. Now, in terms of any other criteria for high-risk disease, there remains one other item, and that has to do with tumor burden. There has been a consensus shift, really, in both the IMS and IMWG to attempt to develop a definition of high-risk disease which is based on biologic features rather than empirically observed and potentially temporally dynamic features, such as lactate dehydrogenase. Beta-2 microglobulin remains an independent high-risk indicator, but care must be taken when measuring it, as renal dysfunction can artificially inflate peripheral titers. The consensus conclusion was that a beta-2 microglobulin of at least 5.5 without renal failure should be considered high-risk but should not preclude detailed genomic profiling. So, in conclusion, the novel 2025 IMS-IMWG risk stratification system for myeloma is binary. It's either high-risk disease or standard-risk disease. It's got four criteria. Number one, deletion 17p and/or a TP53 mutation. Clonal cell fraction cut-off, remember, is 20%. Or number two, an IGH translocation - t(4;14), t(14;16), t(14;20) - with 1q gain and/or deletion of 1p. Or a monoallelic deletion of 1p with 1q additional copies or a biallelic deletion of 1p. Or a beta-2 microglobulin of at least 5.5 only when the creatinine is normal. This is a field-defining work that draws on analyses from across the world to put forward a dominant definition of high-risk disease and introduces a new era of biologically informed risk assessment in myeloma. Now, how does this change our clinical approach? FISH must be performed on CD138-enriched samples and should be performed for all patients. Next-generation sequencing should also be performed on all patients. Trials will hopefully now begin to include this novel definition of high-risk multiple myeloma. It does remain to be seen how data from novel therapeutic trials, if stratified according to this novel definition, will be interpreted. Will we find that therapies being evaluated at present have differential effects on myelomas with different genetic lesions? Other unanswered questions also exist. How do we go about integrating this into academic and then community clinical practice? How do we devise public health interventions for low-resource settings? To discuss this piece further, we welcome the esteemed Dr. Nikhil Munshi to the podcast. Dr. Munshi is a world-renowned leader in multiple myeloma and the corresponding author on this paper. As Professor of Medicine at Harvard Medical School, Director of the Multiple Myeloma Effector Cell Therapy Unit, and Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute, he has presided over critical discoveries in the field.  Thank you for joining us, Dr. Munshi. Dr. Nikhil Munshi: Oh, it's my pleasure being here, Michael, to discuss this interesting and important publication. Michael Hughes: I had a few questions for you. So number one, this is a comprehensive, shall we say, monumental and wide-ranging definition for high-risk myeloma. How do you hope this will influence or impact the ways we discuss myeloma with patients in the exam room? And how do we make some of these components recommended, in particular next-generation sequencing, feasible in lower-resource settings? Dr. Nikhil Munshi: So those are two very important questions. Let's start with the first: How do we utilize this in our day-to-day patient care setting? So, as you know well, we have always tried to identify those patients who do not do so well with the current existing treatment. And for the last 30 years, what constitutes a myeloma of higher risk has continued to change with improvement in our treatment. The current definition basically centers around a quarter of the patients whose PFS is less than 2 to 3 years. And those would require some more involved therapeutic management. So that was a starting point of defining patients and the features. As we developed this consensus amongst ourselves - and it's titled as “International Myeloma Society, International Myeloma Working Group Consensus Recommendation” - this IMS-IMWG type of recommendation we have done for many years, improvising in various areas of myeloma care. Now, here, we looked at the data that was existing all across the globe, utilizing newer treatment and trying to identify that with these four-drug regimens, with transplant and some of the immunotherapy, which group of patients do not do as well. And this is where this current algorithm comes up. So before I answer your question straight, “How do we use it?” I might like to just suggest, “What are those features that we have identified?” There are four features which constitute high-risk disease in the newer definition. Those with deletion 17p with 20% clonality and/or TP53 mutation. Number two, patients with one of the translocations - t(4;14), t(14;16), or t(14;20) - co-occurring with 1q amplification or deletion 1p32. And that's a change. Previously, just the translocation was considered high-risk. Now we need a co-occurrence for it to be called high-risk. The third group is patients having biallelic deletion 1p32 or monoallelic deletion 1p32 along with 1q amplification. And finally, patients with high beta-2 microglobulin, more than or equal to 5.5 mg/dL, with normal creatinine less than 1.2 mg/dL. And the question, “How do we use this?” There are multiple areas where we incorporate high-risk features in our treatment algorithm. One of the first areas is where we would consider the induction regimen. If a patient has a high-risk disease, we would definitely consider a four-drug regimen rather than a three-drug regimen, although we are beginning to incorporate four-drug for all groups. That's one important thing. Number two, those are the patients where we do consider consolidation with transplant or maybe in the new world, considering some of the immunotherapeutic consolidation more early or more aggressively. Number three, these are the patients who get a little bit more maintenance therapy. So normally, lenalidomide might end up being our standard maintenance regimen. In patients who have high-risk disease, we incorporate either addition of daratumumab or the anti-CD38 targeting antibody and/or addition of proteasome inhibitor, either bortezomib or carfilzomib. So you would have multi-drug maintenance therapy in these patients. And in high-risk patients, we follow them with maintenance longer periods of time. One very critically important point to keep in mind is that to get the better outcome in high-risk disease, we must try to get them into MRD negativity because there is clear data that patients who do achieve MRD negativity, despite having high-risk disease, have a much superior outcome. They become near to standard-risk disease. And so, in high-risk patients, I would try to do whatever various options I have to try and get them into MRD-negative status. And when these patients relapse, we do not wait for the classic progression criteria to be met before we intervene. We would propose and suggest that we intervene earlier before the disease really blasts off. And so there are a number of areas in our setting where this high-risk definition will help us intervene appropriately and also with appropriate aggressiveness to achieve better outcome, to make this similar to standard-risk disease. Michael Hughes: Thank you, Dr. Munshi. And thoughts on how to really integrate this not only into academic centers but also lower-resource settings? Dr. Nikhil Munshi: So that's a very important question, Michael. And when we were developing this consensus, we were very cognizant of that fact. So wherever available, I think we are recommending that over a period of next 2, 3, 5 years, we should begin to switch over to sequencing-based methods because two components of this definition, one is TP53 mutation, which we cannot do without sequencing, and also reliably detecting deletion 1p requires sequencing-based method. So in the low-resource countries - and there are many in this world, and also even in our own country, patients may not be able to afford it - the older method with FISH or similar such technology, which is more affordable, is also acceptable for current time. They may miss a very small number of patients, maybe 2% to 3%, where these finer changes are not picked up, but a majority of this would be captured by them. So the current practice might still be applicable with some limitation in those patient populations, and that's what we would recommend. What is happening, fortunately, is that actually sequencing-based method is becoming cheaper. And in many centers, it is cheaper to do the sequencing rather than to do the FISH analysis. And so my hope is that even in low-resource centers, sequencing might be more economical in the end. It's, I think, the access to technology, which is a little bit limited currently, but it's hopefully becoming available soon. Michael Hughes: Thank you, Dr. Munshi. And staying for a minute and looking at the multiple myeloma subsets which might be missed by this really still very broad-ranging high-risk definition, at least by prior risk stratification systems, right, there is this group of patients who have standard-risk cytogenetics by R-ISS or R2-ISS, but they have primary refractory disease or they relapse early. We call these, as you are well aware, functionally high-risk disease. What proportion of previously FHR, functionally high-risk, myeloma patients do you expect to be captured by this novel definition? Dr. Nikhil Munshi: So I think the newer definition - and we can look at it both ways, but the newer definition should capture most of the functionally high-risk definition. To put it differently, Michael, there are patients who we know are, as you mentioned, functionally high-risk. Those are the patients who might have plasma cell leukemia, those who might have extramedullary disease, those who might not respond to our four-drug induction. If you don't respond to the four-drug induction, almost by definition, they are high-risk. However, a majority of them have one of the abnormalities that we are describing here. There would be a very small proportion which may not have. And if they do not have, we know one of the important components of this definition here is also that the genome, we know, keeps on evolving. So there may be a very small clone with the high-risk feature which was not obvious in the beginning. Following treatments or following relapse, that clone predominates, and now the patient's disease becomes high-risk.  So the definition would incorporate or would capture these functional high-risk patients, but as you said, in countries where resources are not available, using this functional high-risk would also be helpful and advantageous. Sometimes LDH ends up being a high-risk. In our studies, LDH has not come out to be high-risk anymore because the features we are describing captures most of those patients, but those alternatives, older, can still be considered if other newer techniques are not available. Michael Hughes: Got you. And in terms of these older definitions, yes, that incorporate tumor burden, these empirical observations about how myeloma presents, do you foresee any additional tumor burden indicators being added to future definitions of high-risk disease? Or do you instead see this particular definition as a major waypoint on the journey towards a fully biologically grounded definition of high-risk disease? Dr. Nikhil Munshi: I think your second part is what is going to happen. I think the tumor burden-related definition is being now replaced by the biological or genomic-based definition. And I think at some point, it will be quite fully replaced. One component not here, and it is because one thing, we don't have enough data; number two, we don't know how it will pan out, is also the influence of the microenvironment on the risk definition. For example, the immune system, the immune function, etc. But not enough data exists to suggest how it would change the current definition. So in future, would a definition be totally genomic or it could be more integrative? And my personal guess is that it would be more integrative and that some immune features might come into the picture, especially now that we are using immune-based therapy as a very important component of treatment - CAR T-cells, bispecific, and antibody-based treatments. What role the immune system plays in either supporting tumor or what role suppression of the anti-tumor immunity plays? They all will be important how patient outcomes end up being, and which in turn could translate into how patient's risk stratification might happen. So I think the older tumor burden-related definitions probably will become things of the past. What we have currently proposed and consensus developed is the new path forward, and over time, some microenvironmental influences, if defined and found to be important, may get some more incorporation if it compares favorably with the genomic features. Michael Hughes: Thank you, Dr. Munshi for that enlightening response.  To conclude the podcast, I'd like to look to the future and to the immediate future, what are the next steps for high-risk disease definition between now and discussing an integrated genomic-microenvironment-based definition? Will we see attempts to refine? Will we see a multi-level system, things like this? Dr. Nikhil Munshi: Yeah, so I think the current definition will be here to stay for the next 10 years or so. I think this has been developed using a large amount of data, so we do believe that this will remain fine. It has been validated now within the last six months by a few of the other studies. So there won't be a quick change. But we will try to, all of us will try to innovate. And as you very rightly bring up, the areas of research would include looking at the expression or transcriptomic component. Does that matter? And we do believe a small number of patients will have transcriptomic changes, not looked at the DNA changes, and may play a role. There are newer components, so long non-coding RNA, for example, is going to be an important component to look at, how it impacts the disease outcome, etc. There are also some of the proteomic-related changes which may become important in our studies. And then as we discussed, microenvironment and immunological changes. So these are the future areas of ongoing research where we all should collect data, and then in the next 5 to 10 years, we'll have another group meeting to see has anything changed or any of the features have become more important.  Most of the time, some of the older features are lost because they are not as critically high-risk, and the newer features come in. And so the historical background for just one second, there was a time when chromosome 13 was considered a high-risk disease. We now don't even mention it because it's not high-risk. The newer treatments have improved the outcome. t(4;14) used to be a high-risk disease. Now by itself today, in this definition by itself is not; it needs to be with something else. And so I think this is a great sign of progress. As we improve the treatment and outcomes, some of the features will become less important, new features will come up, and we'll need to keep on evolving with time and with technology and make it better for patients. Michael Hughes: Thank you so much, Dr. Munshi, for your wisdom, for your sagacity, for your historical perspective as well.  Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries. And be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

High-risk merchant accounts are one of the most challenging areas in payments. In this week's episode, James Shepherd interviews Jerry Gialanella from Fort Point Payments to break down what it really takes to get high-risk deals approved, the pitfalls to avoid, and how their team gets it done. Afterward, Rich Norton shares actionable sales tips from the field, and Patti Murphy joins James for Today in Payments to discuss major industry shifts—from stablecoin developments and Bitcoin trends to PayPal's latest moves and the GENIUS Act.

From the Best of What On Earth – Wildland firefighters say working conditions threaten the safety of crew and the public in Alberta. People on the front lines say they're losing team members to other employers that offer better pay, benefits and long-term opportunities – leaving what they call a gap in experience on the crews. In the midst of what is shaping up to be Canada's second-worst wildfire season, we revisit our conversation.

What do a brothel in Thailand, ancient Egyptian tombs, and Hollywood's lightsabers have to do with the world's most successful innovators? More than you'd ever imagine.In this jaw-dropping episode of Thrive LouD with Lou Diamond, host Lou sits down with the remarkable Susan Lindner—global keynote speaker, founder of Innovation Storytellers, and a woman whose journey to innovation storytelling began in the most unexpected of places.Episode Highlights:From Brothel to Boardroom: Susan shares her origin story as an HIV educator in 1990s Thailand, working with brothel owners and sex workers to reimagine their roles as heroes of their own stories—a lesson that transformed how life-saving innovations can change behavior and lives.The Real Role of Storytelling in Innovation: Discover why most innovators fail at storytelling, focusing on their inventions instead of the impact they have on actual people. Susan reveals the secret: make the listener the hero, not the creator.Hollywood, Prophets, and Going Viral: What can innovators learn from religious prophets and Star Wars? Susan breaks down how innovations (just like lightsabers) are only as good as the stories told about them—and those stories must be simple, repeatable, and transformative.Overcoming Ego & Building Empathy: Explore the practical exercises Susan uses to help scientists, executives, and even Air Force leaders shift from ego-driven narratives to human-centered stories of struggle, triumph, and transformation.The Power of Distribution: It's not just about telling your innovation's story—it's about getting others to tell it for you. Learn Susan's “prophets' playbook” for building a tribe of storytellers inside and outside your organization.Keep Learning: Subscribe to Susan's newsletter (innovationstorytellers.com) and check out the Innovation Storytellers podcast for weekly inspiration and how-tos from global innovation leaders.Whether you're an entrepreneur, scientist, exec, or just someone trying to make your idea stick, this conversation will forever change how you see—and tell—the story of innovation.Listen now and start transforming how you share your ideas, influence others, and make your innovation go viral.Timestamped Overview00:00 Fighting HIV in Thailand's Brothels03:47 Transforming Brothels: Heroes and Change10:02 Overcoming Ego in Innovation11:45 "Understanding Innovator's Humanity"16:38 "Shifting Perspectives: Gaining Early Adopters"19:58 High Risk, High Innovation23:20 Training Air Force Storytellers24:20 Innovation Storytelling Tips28:26 "Innovation Storytelling Podcast Launch"

In today's episode, crypto OG Scott Melker joins us to break down why this might be the most bullish setup for Bitcoin ever, and whether Ethereum is about to rip past expectations. We dive into ETH/BTC breaking key resistance, new liquidity entering the market, and why crypto-adjacent stocks are becoming the new altcoins.~~~~~

Moderator: James P. Rathmell, M.D. Participants: Nikolay O. Kamenshchikov, M.D. and Lorenzo Berra, M.D. and Kamrouz Ghadimi, M.D. Articles Discussed: Perioperative Nitric Oxide Conditioning Reduces Acute Kidney Injury in Cardiac Surgery Patients with Chronic Kidney Disease (the DEFENDER Trial): A Randomized Controlled Trial Nitric Oxide and Kidney Injury after Cardiac Surgery: A Solution Looking for a Problem

In this episode, Ethereum co-founder Joe Lubin breaks down his boldest move yet: launching SBET, a publicly traded ETH treasury vehicle modeled after Michael Saylor's Bitcoin playbook. From geopolitical shifts and stablecoin dominance to Ethereum's evolving value thesis, Joe lays out why ETH is becoming the backbone of the next financial era, and why now is the moment institutions are loading up.~~~~~

In today's episode, we sit down with Nic Huntley, CEO of Blueprint Finance, who's building the infrastructure that could finally bridge traditional finance and onchain yield. We unpack what's really going on behind the scenes, the ETFs, the treasury strategies, and the hidden middleware that could funnel billions into DeFi without anyone even logging into MetaMask.~~~~~

Google and Microsoft issue critical updates. CISA warns of active exploitation of a critical flaw in Wing FTP Server. Cloudflare restores their DNS Resolver service following a brief outage. A critical vulnerability in a PHP documentation tool allows attackers to execute code on affected servers. NSA and FBI officials say they've disrupted Chinese cyber campaigns targeting U.S. critical infrastructure. A UK data breach puts Afghan soldiers and their families at risk. Researchers find malware hiding in DNS records. A former U.S. Army soldier pleads guilty to charges of hacking and extortion. Ben Yelin joins us with insights on the Senate Armed Services Committee's response to rising threats to critical infrastructure.The large print giveth and the small print taketh away.  Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our daily intelligence roundup, Daily Briefing, and you'll never miss a beat. And be sure to follow CyberWire Daily on LinkedIn. CyberWire Guest Today we are joined by Ben Yelin, co host of our Caveat podcast and Program Director for Public Policy & External Affairs at the University of Maryland Center for Cyber Health and Hazard Strategies, discussing the Senate Armed Services Committee's and Trump administration nominees' recent conversation about rising threats to critical infrastructure. You can find the article Ben discusses here. Selected Reading Google fixes actively exploited sandbox escape zero day in Chrome (Bleeping Computer) Windows KB5064489 emergency update fixes Azure VM launch issues (Bleeping Computer) Exploited Wing file transfer bug risks ‘total server compromise,' CISA warns (The Record) Cloudflare 1.1.1.1 incident on July 14, 2025 (Cloudflare) Critical template Injection flaw in LaRecipe Documentation Package enables remote code execution (Beyond Machines) NSA: Volt Typhoon was ‘not successful' at persisting in critical infrastructure (The Record) Defence secretary 'unable to say' if anyone killed after Afghan data breach  (BBC News) Hackers exploit a blind spot by hiding malware inside DNS records (Ars Technica) 21-year-old former US soldier pleads guilty to hacking, extorting telecoms  (The Record) WeTransfer says files not used to train AI after backlash (BBC News) Audience Survey Complete our annual audience survey before August 31. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at cyberwire@n2k.com to request more info. The CyberWire is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

This podcast highlights three updates: Moderna's Spikevax COVID-19 vaccine is now fully FDA-approved for high-risk children 6 months to 11 years, though rare myocarditis remains a concern. A large study found first-trimester TMP-SMX antibiotics increase congenital malformation risks compared to β-lactams, reinforcing β-lactams as safer. Finally, a trial showed no cardiovascular benefit from taking blood pressure medication at bedtime versus morning dosing.

We have covered Low Dose Aspirin (LDA) for pre-natal preeclampsia prevention MANY times before. But here's a good clinical question: Since preeclampsia can also pop-up in the first 6 weeks postpartum (pp), should we continue it in the immediate pp interval? There is a new publication, an RCT, in the AJOG that looked to answer this- and we will highlight that publication in this episode. PLUS, we will briefly summarize a separate publication from the American J Perinatology back in 2023 that also provided some clinical insights on this topic. Listen in for details.1. The association between postpartum aspirin use and NT-proBNP levels as a marker for maternal cardiac health: a randomized-controlled trial; July 2025 (AJOG): https://www.sciencedirect.com/science/article/pii/S00029378250047522. Christenson E, Stout MJ, Williams D, Verma AK, Davila-Roman VG, Lindley KJ. Prenatal Low-Dose Aspirin Use Associated with Reduced Incidence of Postpartum Hypertension among Women with Preeclampsia. Am J Perinatol. 2023 Mar;40(4):394-399. doi: 10.1055/s-0041-1728826. Epub 2021 May 3. PMID: 33940641.3. Mendoza M, Bonacina E, Garcia-Manau P, et al. Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. JAMA. 2023;329(7):542–550. doi:10.1001/jama.2023.0691

Do you really know your breast cancer risk? Many women think they do – trusting family history, regular checkups, and mammograms to keep them safe. But what if these measures leave dangerous blind spots, leading to later, more aggressive diagnoses? Today's episode is a powerful wake-up call. Joining us is globally renowned OBGYN, Dr. Thaïs Aliabadi. Known simply as “Dr. A” to her global following, she's OBGYN to royals and celebrities, and a leading voice on women's health featured on The Kardashians, The Doctors, and Dr. Phil. Dr. Aliabadi shares her own shocking story: how, despite following all the rules, she uncovered a hidden cancer risk that standard screening completely missed. Today you'll learn why your lifetime risk may be higher than you've been told, how diet and lifestyle could change your trajectory, and the essential steps to take today to safeguard your health. This is information every woman needs - don't wait until it's too late. Unwrap the truth about your food

After losing 3 lbs out of his less than 30 pound frame and not eating well in late 2021, Shelby Nadeau took her son Stryder to doctors, neither of whom thought that there was anything wrong with him physically. Just a couple of weeks later however, Stryder was diagnosed with Stage 4 High Risk Neuroblastoma after proper tests were ordered at Sacramento Children's Hospital which showed that there were plenty of tumors to be found. 

In this episode, I was lucky enough to interview Aubrey Amatelli, Founder and CEO of PayRio—the first payment provider focused exclusively on alternative medicine.Aubrey shared how her roots in Silicon Valley and a traditional finance career at JP Morgan eventually led her to launch PayRio, combining her passion for cannabis and her expertise in payments. She walked me through the complicated regulatory landscape that makes payment processing for cannabis so challenging and explained how PayRio uses creative, compliant workarounds like ATM rails and wallet tech to support dispensaries and e-commerce businesses.Aubrey also opened up about the emotional transition from corporate life to cannabis entrepreneurship, including the fear and eventual empowerment that came with “coming out” on LinkedIn. Aubrey discussed how her startup journey began with cold calls and a scrappy three-person team, and how PayRio has grown to serve both mom-and-pop dispensaries and multi-state operators alike.Let's drive all the way to San Francisco and dive into Aubrey Amatelli's bold leap from Wall Street to CBD tech in this episode of The First Customer!Guest Info:PayRiohttps://payrio.co/Aubrey Amatelli's LinkedInhttps://www.linkedin.com/in/aubreyamatelli/Connect with Jay on LinkedInhttps://www.linkedin.com/in/jayaigner/The First Customer Youtube Channelhttps://www.youtube.com/@thefirstcustomerpodcastThe First Customer podcast websitehttps://www.firstcustomerpodcast.comFollow The First Customer on LinkedInhttp://www.linkedin.com/company/the-first-customer-podcast/

All kink carries some level of risk but certain activities are known to be genuinely dangerous. Should kinksters who engage in these scenes – with full consent from both parties – be “allowed” to... The post Ethics and Responsibilities in High-Risk Kink Play appeared first on Loving BDSM.

Fantasy Football show for June 5, 2025. It's mock draft time! Lots of advice for 2025 fantasy football drafts! Find out which strategies worked best in a 10-team Half PPR mock draft. Plus, the riskiest picks and upside players who could take a step forward in 2025. Manage your redraft, keeper, and dynasty fantasy football teams with the #1 fantasy football podcast.2025 ULTIMATE DRAFT KIT is available now at UltimateDraftKit.com(00:00) Introduction(03:20) NFL News12:00) Mock DraftConnect with the show:Subscribe on YouTubeVisit us on the WebSupport the ShowFollow on XFollow on InstagramJoin our Discord

They say you should never meet your heroes. Daemon Fairless disagrees. First, he has an update on the return of Hunting Warhead. But then he takes us behind-the-scenes on another project he's been working on as a story editor: The Outlaw Ocean.This is a frank, illuminating discussion with Ian Urbina, the Pulitzer Prize winning journalist who quit his New York Times job to do some of the hardest, most difficult and often dangerous reporting in the world. He's since become the de facto beat reporter for the world's oceans — and his investigations reveal the shocking prevalence of forced labour, mind-boggling overfishing, and the hard truth is that it's all connected to the cheap seafood we love.If you have the stomach for the kind of viscerally tough reporting we do on Hunting Warhead, we know you'll appreciate The Outlaw Ocean — another show that sheds light on the darkest corners of the world, and goes where others won't.Find and follow The Outlaw Ocean (S2) here: https://link.mgln.ai/oo-hw